GLAXO Intraday Analysis...

GLAXO Share Price

Open 2725.00 Change Price %
High 2774.40 1 Day -1.40 -0.05
Low 2725.00 1 Week 16.50 0.61
Close 2738.05 1 Month 83.50 3.15
Volume 5957 1 Year -532.20 -16.27
52 Week High 3872.00
52 Week Low 2600.00
GLAXO Important Levels
Resistance 2 2783.84
Resistance 1 2764.97
Pivot 2745.82
Support 1 2711.13
Support 2 2692.26
NSE INDIA Most Active Stocks
IFCI 27.25 16.45%
VISESHINFO 0.40 0.00%
SAIL 55.25 3.17%
SBIN 266.65 2.60%
ICICIBANK 268.45 2.17%
JINDALSTEL 74.20 1.50%
TANLA 59.75 19.98%
HCL-INSYS 61.30 1.07%
SUZLON 14.75 -1.01%
VEDL 245.45 1.03%
More..
NSE INDIA Top Gainers Stocks
VKSPL 0.15 50.00%
SFL 1032.00 41.37%
SFL 1032.00 41.37%
SFL 1032.00 41.37%
RASOYPR 0.20 33.33%
PARASPETRO 0.25 25.00%
VIMALOIL 43.20 20.00%
ATNINTER 0.30 20.00%
EUROTEXIND 33.60 20.00%
TANLA 59.75 19.98%
More..
NSE INDIA Top Losers Stocks
INDIANHUME 400.40 -51.39%
SPYL 1.75 -18.60%
SURANAIND 3.85 -15.38%
GLOBOFFS 94.85 -14.43%
SRGINFOTEC 0.30 -14.29%
KARMAENG 51.80 -9.44%
BANARBEADS 46.00 -8.46%
ZENITHBIR 0.65 -7.14%
AUSOMENT 33.05 -7.03%
ASIL 0.70 -6.67%
More..

GlaxoSmithKline Pharmaceuticals Limited (NSE: GLAXO)

GLAXO Technical Analysis 4
As on 9th Dec 2016 GLAXO Share Price closed @ 2738.05 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3224.88 & Sell for SHORT-TERM with Stoploss of 2801.64 we also expect STOCK to react on Following IMPORTANT LEVELS.
GLAXO Target for December
1st Target up-side 2916.89
2nd Target up-side 3058.95
3rd Target up-side 3201.02
1st Target down-side 2511.51
2nd Target down-side 2369.45
3rd Target down-side 2227.38
GLAXO Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 49.33 Sideways
MFI (14) MFI is 55.36 Sideways
CCI (20) CCI is Above 100 Over Bought
WILLIAM %R (14) William %R is -26.18 Sideways
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Long Buy 2656.72
10 Day Avg Volume Traded -19.66 % Less then 10 Day Average Volume
GLAXO Other Details
Segment EQ
Market Capital 94531387392.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.gsk-india.com
GLAXO Address
GLAXO
Dr. Annie Besant Road
Mumbai, 400030
India
Phone: 91 22 2495 9595
Fax: 91 22 2495 9494
GLAXO Latest News
IPO Report: SteadyMed (STDY)   Equities.com   - 20th Mar 15
Pharmaceutical, Biotech Mergers Set Record in 2014   Pharmaceutical Processing   - 19th Mar 15
A Decade Old Drug Launch In China With Important Insights Today   Forbes   - 18th Mar 15
MGM and Black Diamond Are Big Market Movers   New York Times   - 17th Mar 15
Business news in brief   Philly.com   - 14th Mar 15
India's Sun Pharma to buy GSK's opiates business in Australia   Reuters   - 03rd Mar 15
GSK Pharma to move cancer drug portfolio to Novartis arm   Moneycontrol.com   - 12th Feb 15
GlaxoSmithKline Pharmaceuticals Ltd clarifies on CCI nod   Equity Bulls   - 26th Dec 14
CCI clears Novartis-GSK pharma deal   Moneycontrol.com   - 23rd Dec 14
GlaxoSmithKline Pharmaceuticals Announces Q3 Results   Business Wire India (press release)   - 06th Nov 14
Interactive Technical Analysis Chart GlaxoSmithKline Pharmaceuticals Limited ( GLAXO NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on GlaxoSmithKline Pharmaceuticals Limited
GLAXO Business Profile
Incorporated in 1924 as H J Foster and Co, Glaxo India became a wholly-owned subsidiary of Joseph Nathan and Co., UK. Later in 1947, the company was renamed as Glaxo Laboratories (India). In 2000, Glaxo Wellcome plc and SmithKline plc merged under an agreement to form a new company, named GlaxoSmithKline plc. With this merger, Glaxo India is now an affiliate of GlaxoSmithKline plc, which holds 51 per cent of the equity. Its principal products are, Betamethasone based topical steroids, Betnovate-C, Betnovate-M, and Betnovate- GM. It also makes tablets from the same pharmaceutical ingredient, which is marketed under the brand name Betnesol. Its other key products are Cephalosporin, Ceftum, H2 blocker based on Ranitidine, Zinetac and the vitamin Celin. Glaxo manufactures the bulk drug from the basic stage, furfuryl alcohol, employing the technology developed by its parent, Glaxo Wellcome, UK. The company also markets over-the-counter (OTC) medicines, dental products, smoking control products and nutritional healthcare drinks. Occupying a 6.5 per cent market share (2005), the company has Biddle Sawyer as its subsidiary. The company recently launched four new products licensed from companies in the US and Japan viz. Parit (Rabeprazole) in alliance with Eisai, Japan, Ferronine (a novel chelated iron) in alliance with Albion, USA and two new oral contraceptives in alliance with Organon. GSK plans to focus on the development of new technologies for Betamethasone, Clobetasone, Clobetasol and collaborative research work with GlaxoSmithKline - R&D, UK. The current market capitalization stands at Rs 20,328.72 crore. The company has reported a standalone sales of Rs 626.65 crore and a Net Profit of Rs 100.95 crore for the quarter ended September 2013. The company management includes D S Parekh - Chairman, V Thyagarajan - Vice Chairman, H B Joshipura - Managing Director, R R Bajaaj - Director, S Harford - Director, M B Kapadia - Director, P V Bhide - Director, R Krishnaswamy - Director, P V Nayak - Director, A N Roy - Director, R C Sequeira - Director, Anjali P Bansal - Ind. Non-Executive Director. The Registered office is at Dr. Annie Besant Road , Mumbai, Maharashtra - 400030.